Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the diseaseGeorg Jeryczynski, Heinz Gisslinger, Jürgen Thiele et al.|American Journal of Hematology|2017Cited by 66
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaHeinz Gisslinger, J. Thiele, Sonja Burgstaller et al.|Leukemia|2015Cited by 62
Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical dataMartin Schalling, Heinz Gisslinger, Andreas Gleiß et al.|Blood Cancer Journal|2017Cited by 20
Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statementThamer Sliwa, Heinz Gisslinger, Christine Beham‐Schmid et al.|Wiener klinische Wochenschrift|2016Cited by 9
Erratum: Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaHeinz Gisslinger, J. Thiele, Georg Jeryczynski et al.|Leukemia|2017Cited by 8